# A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

> **NCT02896855** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 243 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Pertuzumab
- **DRUG:** Placebo
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02896855
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-13
- **Primary completion:** 2018-06-27
- **Final completion:** 2021-01-22
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896855, "A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02896855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*